You are viewing the site in preview mode

Skip to main content

Table 1 Details of included studies

From: Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions

Trial ID Sponsor Drug Comparison Phase Total participants Age eligibility N (%) aged ≥ 65 Mean (SD) age N (%) female
T2DM
 NCT01106625 Janssen Canagliflozin Placebo 3 469 18–80 years 84 (17%) 56.7 (9.3) 230 (40%)
 NCT01106677 Janssen Canagliflozin Placebo 3 1284 18–80 years 206 (16%) 55.4 (9.4) 679 (53%)
 NCT00734474 Lilly Dulaglutide Sitagliptin, Placebo/Sitagliptin 3 1202 18–75 years 364 (30%) 54.1 (9.9) 643 (54%)
 NCT01064687 Lilly Dulaglutide Exenatide, Placebo 3 978 ≥ 18 years 197 (20%) 55.7 (9.8) 406 (42%)
 NCT01075282 Lilly Dulaglutide Insulin 3 810 ≥ 18 years 188 (23%) 56.7 (9.5) 393 (49%)
 NCT01191268 Lilly Dulaglutide Insulin 3 884 ≥ 18 years 280 (32%) 59.3 (9.2) 411 (57%)
 NCT01624259 Lilly Dulaglutide Liraglutide 3 599 ≥ 18 years 138 (23%) 56.7 (9.3) 312 (52%)
RA
 NCT00236028 Janssen Infliximab Methotrexate 3 1036 18–75 years 127 (12%) 50 (12.6) 733
 NCT00264537 Janssen Golimumab Placebo 3 637 ≥ 18 years 52 (8%) 49.5 (12.2) 528 (83%)
 NCT00264550 Janssen Golimumab Placebo 3 444 ≥ 18 years 38 (9%) 50.4 (11.3) 358 (81%)
 NCT00361335 Janssen Golimumab Placebo 3 643 ≥ 18 years 46 (7%) 49.4 (11.7) 517 (18%)
 NCT00106535 Roche Tocilizumab Placebo 3 1196 ≥ 18 years 173 (14%) 52.0 (12.2) 989 (83%)
 NCT01119859 Roche Tocilizumab Adalimumab 4 326 ≥ 18 years 75 (23%) 53.9 (12.7) 262 (81%)
 NCT01007435 Roche Tocilizumab Placebo 3 1162 ≥ 18 years 180 (15%) 50.1 (13.5) 904 (78%)
 NCT01232569 Roche Tocilizumab Placebo 3 656 ≥ 18 years 81 (12%) 52.1 (11.5) 555 (85%)
COPD
 NCT01316913 GSK Umeclidinium bromide Tiotropium 3 872 ≥ 40 years 455 (52%) 64.6 (8.4) 280 (32%)
 NCT01316900 GSK Umeclidinium bromide Tiotropium 3 846 ≥ 40 years 364 (43%) 62.9 (9.0) 261 (31%)
 NCT01957163 GSK Umeclidinium bromide Fluticasone, Placebo 3 619 ≥ 40 years 299 (48%) 64.4 (8.1) 212 (32%)
 NCT02119286 GSK Umeclidinium bromide Fluticasone, Placebo 3 620 ≥ 40 years 270 (44%) 62.9 (8.2) 228 (37%)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us